Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Shire Plc. : arGEN-X enters into a therapeutic antibody alliance with Shire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/29/2012 | 11:01am CET

Rotterdam, the Netherlands and Ghent, Belgium February 29, 2012- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

Using its cutting edge SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has identified and that are known to contribute to the pathophysiology of severe, rare genetic diseases. arGEN-X will also bring its state-of-the-art antibody capabilities to the collaboration for the preclinical characterization of therapeutic leads. Shire has the option to license the most promising leads for further preclinical and clinical development and commercialization worldwide.

Under the terms of the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments. In return for its option to develop and commercialize products on an exclusive basis, Shire will pay fees, milestones and royalties on product sales. Specific details of the financial terms were not disclosed.

Tim Van Hauwermeiren, CEO of arGEN-X, said, "We are delighted to pioneer human antibodies as novel, first-in-class therapies for rare diseases with a partner of Shire's calibre. Shire's depth of experience in protein-based therapies is the perfect complement to our own discovery capabilities. We are confident that our SIMPLE Antibody™ platform, which consistently delivers antibodies of therapeutic quality against complex targets often intractable with other technologies, will bring significant value to this alliance. We believe this alliance represents an industry first and we are looking forward to an exciting and productive collaboration with Shire."

"As a leader in innovative therapies for rare diseases, Shire is continuing to apply new technologies to address the needs of patients," said Philip J. Vickers, Senior Vice President, Research and Development, Shire Human Genetic Therapies (HGT). "Monoclonal antibody therapy is an underutilized approach to the treatment of rare diseases, and this novel platform has the potential to bring multiple drug candidates into our early-stage pipeline. Partnerships such as this one with arGEN-X are an important part of our strategy to bring new therapies to those suffering from rare diseases worldwide."

About arGEN-X- www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging the power of its broadly applicable, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery enables it to prioritise leads with best-in-class therapeutic properties, thereby increasing the probability of development success. Antibody leads generated from the SIMPLE Antibody™ platform have outstanding physicochemical properties and consistent manufacturability, enabling a seamless transition from discovery into development. arGEN-X has validated its technology on multiple diverse classes of target to date and has successfully delivered in its collaboration with Eli Lilly & Co..

arGEN-X' SIMPLE Antibody™ platform is based on the active immunization of Camelids with target antigens to deliver antibody variable regions that are essentially identical to those of human antibodies. arGEN-X is able to generate full size, human therapeutic antibodies by combining these variable regions with human constant domains.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands forSuperiorI mmunodiversity withMinimalP roteinLeadE ngineering.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

For further information, please contact:

Citigate Dewe Rogerson
arGEN-X
David Dible
Tim Van Hauwermeiren, MSc, eMBA
Mark Swallow
Chief Executive Officer
Nina Enegren
T: +31 6 122 85 257
T: +44 207 282 2949/2948/1050
E: tim.vh@arGEN-X.com
E: david.dible@citigatedr.co.uk
Debbie Allen, Ph.D.
Senior Director, Business Development
T: +44 7974 979479
E: dallen@arGEN-X.com
Shire - Human Genetic Therapies US
Shire Corporate
Jessica Cotrone
Jessica Mann
T: +1 781 482 9538
T: +44 1256 894280
jcotrone@shire.com
E: jmann@shire.com


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
11/22 European shares retreat on euro bounce; UK flat after budget
11/22 FTSE gets sterling boost, land purchase threat dents housebuilders
11/21 Shire appoints Thomas Dittrich as CFO
11/20 SHIRE : to Appoint Thomas Dittrich as Chief Financial Officer and Member of the ..
11/20 FTSE recoups early losses as cyclicals recover
11/20 Highly Anticipated Agenda Released for Pre-Filled Syringes East Coast 2018
11/20DJSHIRE : Appoints Thomas Dittrich as Chief Financial Officer
11/20DJSHIRE PLC SHIRE PLC : Directorate Change
11/20 SHIRE PLC : Directorate change
11/17 British stocks fall back as Carillion crashes, Sky soars
More news
News from SeekingAlpha
11/22 MAIN STREET CAPITAL : One Out Of Two
11/21 BIOTECH FORUM DAILY DIGEST : What Now For Sarepta?
11/21 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
11/20 Shire and Bioverativ under pressure premarket on Roche's positive Hemlibra da..
11/20 Roche Obtains FDA Approval For Hemophilia A Drug, Time To Push Shire Out
Financials ($)
Sales 2017 14 910 M
EBIT 2017 5 666 M
Net income 2017 2 482 M
Debt 2017 19 314 M
Yield 2017 0,75%
P/E ratio 2017 17,07
P/E ratio 2018 12,03
EV / Sales 2017 4,22x
EV / Sales 2018 3,81x
Capitalization 43 671 M
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 68,4 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Matt Walker Head-Technical Operations
David R. Ginsburg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-21.47%43 671
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014